Abbott Laboratories's Revenue in the fiscal year 2025 $ 44,328.00 millions
Abbott Laboratories's Revenue in the fiscal year 2024 $ 41,950.00 millions
Abbott Laboratories's Revenue in the fiscal year 2023 $ 40,109.00 millions
Abbott Laboratories's Revenue in the fiscal year 2022 $ 43,653.00 millions
Abbott Laboratories's Revenue in the fiscal year 2021 $ 43,075.00 millions
ABT Revenue first quarter 2026 Y/Y Growth Comment
Abbott Laboratories achieved in the first quarter 2026, above Company average Revenue improvement of 7.78% year on year, to $ 11,164.00 millions.
Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 105 other companies have achieved higher Revenue growth. While Abbott Laboratories' s Revenue increase of 7.78% ranks overall at the positon no. 1867 in the first quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Abbott Laboratories's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
85.61 %
1.81 %
-50.37 %
(June 30. 2012)
ABT's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Abbott Laboratories disclosed fall in Revenue from the fourth quarter by -2.57% to $ 11,164.00 millions, from $ 11,459.00 millions achived in the previous reporting period.
But that's not important problem, as Abbott Laboratories's Revenue generally seem to plunge in this quarter.
Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Abbott Laboratories's Revenue growth quarter on quarter, overall rank is 1382.
In the I. Quarter 2026 Abbott Laboratories disclosed fall in Revenue from the fourth quarter by -2.57% to $ 11,164.00 millions, from $ 11,459.00 millions achived in the previous reporting period.
But that's not important problem, as Abbott Laboratories's Revenue generally seem to plunge in this quarter.
Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Abbott Laboratories's Revenue growth quarter on quarter, overall rank is 1382.
Abbott Laboratories's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
12 Months Ending (Mar 31 2025)
Cumulative Revenue 12 Months Ending
$ 45,134.00
$ 44,328.00
$ 43,843.00
$ 43,109.00
$ 42,344.00
Y / Y Revenue Growth (TTM)
6.59 %
5.67 %
6.37 %
5.85 %
5 %
Year on Year Revenue Growth Overall
Ranking
# 2058
# 722
# 1868
# 600
# 2050
Seqeuential Revenue Change (TTM)
1.82 %
1.11 %
1.7 %
1.81 %
0.94 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1828
# 871
# 2062
# 1964
# 2078
Cumulative Revenue growth Comment
Abbott Laboratories saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 6.59% year on year, to $ 45,134 millions if the fiscal year would have ended in Mar 31 2026. Abbott Laboratories's trailing twelve months Revenue growth was higher than company's average 4.9% and higher than 5.67% growth in Dec 31 2025. But from twelve months ended Dec 31 2025 rise was beneth at 1.82 % from $44328 millions achieved in the period from Dec 31 2025 to Mar 31 2025. We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at5.05%. The momentum is even more impressive from twelve months ended Dec 31 2025 exhibited at 1.82 % increase from $44328 millions in the period from Dec 31 2025 to Mar 31 2025.
In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 722 to 2058.
Abbott Laboratories saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 6.59% year on year, to $ 45,134 millions if the fiscal year would have ended in Mar 31 2026. Abbott Laboratories's trailing twelve months Revenue growth was higher than company's average 4.9% and higher than 5.67% growth in Dec 31 2025. But from twelve months ended Dec 31 2025 rise was beneth at 1.82 % from $44328 millions achieved in the period from Dec 31 2025 to Mar 31 2025. We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at5.05%. The momentum is even more impressive from twelve months ended Dec 31 2025 exhibited at 1.82 % increase from $44328 millions in the period from Dec 31 2025 to Mar 31 2025.
In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 722 to 2058.
About Abbott Laboratories Revenue Growth Rates (ABT), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
13.33%